KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Cash (2020 - 2025)

Historic Change in Cash for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$9.3 million.

  • AbCellera Biologics' Change in Cash rose 5718.9% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year increase of 502.39%. This contributed to the annual value of $23.0 million for FY2024, which is 10905.57% up from last year.
  • Latest data reveals that AbCellera Biologics reported Change in Cash of -$9.3 million as of Q3 2025, which was up 5718.9% from -$66.8 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Change in Cash high stood at $245.8 million for Q2 2022, and its period low was -$417.4 million during Q3 2022.
  • Over the past 5 years, AbCellera Biologics' median Change in Cash value was -$9.3 million (recorded in 2025), while the average stood at -$25.5 million.
  • Examining YoY changes over the last 5 years, AbCellera Biologics' Change in Cash showed a top increase of 34135.08% in 2021 and a maximum decrease of 114626.86% in 2021.
  • Over the past 5 years, AbCellera Biologics' Change in Cash (Quarter) stood at -$16.6 million in 2021, then soared by 187.98% to $14.6 million in 2022, then plummeted by 368.51% to -$39.1 million in 2023, then skyrocketed by 175.92% to $29.7 million in 2024, then crashed by 131.25% to -$9.3 million in 2025.
  • Its Change in Cash was -$9.3 million in Q3 2025, compared to -$66.8 million in Q2 2025 and $2.9 million in Q1 2025.